Aldose reductase is an important enzyme in the pathway involved in the pathogenesis of dry eye and oral administration of aldose reductase inhibitors has been demonstrated to improve tear dynamics [17, 18]. This evidence concerns the gene AKR1B1 and Keratoconjunctivitis sicca.